Trimethoprim-Sulfamethoxazole ( DrugBank: Trimethoprim, Sulfamethoxazole )

3 diseases

ID	Disease name (Link within this page)	Number of trials
49	Systemic lupus erythematosus	1
61	Autoimmune hemolytic anemia	1
299	Cystic fibrosis	1

49. Systemic lupus erythematosus

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03042260 (ClinicalTrials.gov)	March 1, 2017	10/1/2017	Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous	Prophylactic Trimethoprim-Sulfamethoxazole for the Prevention of Serious Infections in Patients With Systemic Lupus Erythematosus: a Randomized Placebo Controlled Trial	Lupus Erythematosus, Systemic	Drug: Trimethoprim-Sulfamethoxazole;Drug: Placebo Oral Tablet	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	National Council of Science and Technology, Mexico	Recruiting	18 Years	N/A	All	310	Phase 4	Mexico

61. Autoimmune hemolytic anemia

Clinical trials : 146 / Drugs : 131 - (DrugBank : 59) / Drug target genes : 28 - Drug target pathways : 158

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-002844-66-IT (EUCTR)	23/11/2021	23/09/2021	Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia - NA	Primary Warm Autoimmune Hemolytic Anemia MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Parsaclisib (1 mg) Product Code: [INCB050465] Other descriptive name: INCB050465 HYDROCHLORIDE Product Name: Parsaclisib (2.5 mg) Product Code: [INCB050465] Other descriptive name: INCB050465 HYDROCHLORIDE Product Name: trimethoprim-sulfamethoxazole Product Code: [trimethoprim-sulfamethoxazole] INN or Proposed INN: TRIMETOPRIM + SULFAMETOSSAZOLO * Product Name: pentamidine Product Code: [pentamidine] INN or Proposed INN: PENTAMIDINA ISETIONATO Product Name: atovaquone Product Code: [atovaquone] INN or Proposed INN: ATOVAQUONE	INCYTE CORPORATION	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	United States;Spain;Ukraine;Austria;Israel;United Kingdom;Italy;France;Canada;Belgium;Poland;Germany;Netherlands;Japan

299. Cystic fibrosis

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2013-000219-25-IT (EUCTR)	18/07/2013	12/04/2018	MRSA study.	Early eradication of S. Aureus (MRSA) in patients with cystic fibrosis: a randomized multicenter study.	Patients affected by cystic fibrosis and who present an initial infection of MRSA.;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]	Product Name: Rifampin INN or Proposed INN: RIFAMPICIN Product Name: Trimethoprim-sulfamethoxazole INN or Proposed INN: SULFAMETHOXAZOLE Other descriptive name: TRIMETHOPRIM Product Name: minocycline Other descriptive name: MINOCYCLINE HYDROCHLORIDE	AOU Meyer	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	Italy